PTL联合ZD55-TRAIL对肝癌细胞Hep3B生长抑制的研究  

Enhancement of the Growth Inhibiting Effect to Liver Tumor Cell Hep3B by Combining Parthenolide with ZD55-TRAIL

作　　者：李晓艳[1] 马晖[2] 潘强[1] 杨新燕[1] 吴丽琴[1] 陈侃[1] 

机构地区：[1]浙江理工大学生命科学学院新元医学与生物技术研究所,杭州310018 [2]陕西省汉中职业技术学院医学系,汉中723000

出　　处：《中国细胞生物学学报》2013年第5期630-636,共7页Chinese Journal of Cell Biology

基　　金：浙江省科技厅公益性技术应用研究计划(批准号:2012C37069);浙江理工大学科研启动基金(批准号:0916819-Y)资助的课题~~

摘　　要：联合运用NF-κB小分子抑制剂小白菊内酯(parthenolide,PTL)和携带TRAIL的溶瘤腺病毒ZD55-TRAIL在体外杀伤人肝癌细胞株Hep3B,以评估两者联用的实验疗效。首先用Adeasy系统包装ZD55-TRAIL病毒;分别用MTT、结晶紫和Hoechst33342荧光染色实验检测ZD55-TRAIL、ZD55-TRAIL和PTL联合运用对肝癌细胞株Hep3B和正常肝细胞QSG-7701的增殖抑制作用。结果表明:10 MOI ZD55-TRAIL联合PTL处理72 h后,Hep3B细胞的存活率仅为44%,但对QSG-7701细胞无明显损伤;而10 MOI的ZD55-TRAIL和PTL分别单独处理后细胞存活率为70%和66%;结晶紫实验及Hoechst33342染色结果表明联合处理组的Hep3B细胞凋亡特征更加明显。溶瘤腺病毒ZD55-TRAIL联合PTL在体外对肝癌细胞Hep3B具有显著的杀伤性,而对QSG-7701细胞无明显毒副作用。This study aimed at studying the anti-tumor effect in hepatocarcinoma cell Hep3B cells by combin- ing parthenolide （PTL） with ZD55-TRAIL. The experiment was constructed oncolytic adenovirus ZD55-TRAIL by Adeasy systerm. Then MTT, crystal violet and Hoechst33342 staining assay were used to assess the growth inhibition effects of single or combination therapy on liver tumor cell Hep3B and human normal cell QSG-7701. The results showed that 10 MOI ZD55-TRAIL combining with PTL treated for 72 h, Hep3B cells＇ survival rate is only 44%, and no significant damage to the QSG-7701 cells, while in ZD55-TRAIL and PTL 10 MOI separately treated cells, the survival rate is 70% and 66%, respectively. The crystal violet and Hoechst33342 staining results showed that the com- bined treatment group Hep3B apoptotic features more obviously. Oncolytic adenovirus ZD55-TRAIL joint PTL had significant destruction in vitro on heoatoma cells Heo3B. but no significant side effects to OSG-7701 cells.

关 键 词：小白菊内酯(PTL) ZD55-TRAIL 肝癌 

分 类 号：R735.7[医药卫生—肿瘤]